Axsome Therapeutics (NASDAQ:AXSM) Sets New 12-Month High – Here’s Why

Posted by Brenda Bartman on May 15th, 2026

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $235.78 and last traded at $234.2050, with a volume of 426029 shares trading hands. The stock had previously closed at $224.03.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Oppenheimer set a $280.00 price target on Axsome Therapeutics in a research report on Monday, May 4th. Guggenheim upped their price objective on Axsome Therapeutics from $245.00 to $260.00 and gave the company a “buy” rating in a research report on Monday, May 4th. HC Wainwright increased their price objective on Axsome Therapeutics from $270.00 to $290.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Morgan Stanley lifted their price objective on Axsome Therapeutics from $217.00 to $242.00 and gave the stock an “equal weight” rating in a research report on Tuesday, May 5th. Finally, Leerink Partners boosted their target price on shares of Axsome Therapeutics from $150.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Axsome Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $251.26.

Get Our Latest Analysis on AXSM

Axsome Therapeutics Trading Down 2.0%

The business has a 50 day simple moving average of $179.76 and a two-hundred day simple moving average of $168.03. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. The company has a market cap of $11.72 billion, a PE ratio of -61.05 and a beta of 0.59.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The business had revenue of $191.20 million during the quarter, compared to analysts’ expectations of $191.10 million. The firm’s quarterly revenue was up 57.4% compared to the same quarter last year. On average, analysts forecast that Axsome Therapeutics, Inc. will post -2.14 EPS for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In related news, Director Mark Coleman sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $161.11, for a total value of $4,027,750.00. Following the sale, the director directly owned 47,140 shares of the company’s stock, valued at approximately $7,594,725.40. This trade represents a 34.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ari Maizel sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $182.42, for a total transaction of $1,368,150.00. Following the completion of the sale, the insider directly owned 7,500 shares in the company, valued at $1,368,150. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 72,628 shares of company stock worth $12,205,662 in the last 90 days. 20.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Axsome Therapeutics

Large investors have recently bought and sold shares of the stock. Versant Capital Management Inc grew its stake in shares of Axsome Therapeutics by 20,300.0% during the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after buying an additional 203 shares during the period. Kemnay Advisory Services Inc. purchased a new position in shares of Axsome Therapeutics in the 4th quarter worth $31,000. First Horizon Corp purchased a new position in shares of Axsome Therapeutics in the 3rd quarter worth $34,000. Hollencrest Capital Management boosted its holdings in Axsome Therapeutics by 400.0% in the first quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock valued at $34,000 after acquiring an additional 160 shares during the last quarter. Finally, Optiver Holding B.V. boosted its holdings in Axsome Therapeutics by 82.3% in the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after acquiring an additional 130 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

(Get Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.